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Abstract
Background: Cardio-embolic etiology is the most frequently predicted cause of cryptogenic stroke/TIA. Detection
of occult paroxysmal atrial fibrillation is crucial for selection of appropriate medication.
Methods: Enrolment of eligible cryptogenic stroke and TIA patients began in 2014 and will continue until 2018.
The patients undergo long-term (12 months) ECG monitoring (implantable loop recorder) and testing for PITX2
(chromosome 4q25) and ZFHX3 (chromosome 16q22) gene mutations. There will be an appropriate control group
of age- and sex-matched healthy volunteers. To analyse the results descriptive statistics, statistical tests for group
differences, and correlation analyses will be used.
Discussion: In our study we are focusing on a possible correlation between detection of atrial fibrillation by
an implantable ECG recorder, and PITX2 and/or ZFHX3 gene mutations in cryptogenic stroke/TIA patients. A
correlation could lead to implementation of this genomic approach to cryptogenic stroke/TIA diagnostics and
management. The results will be published in 2018.
Trial registration: ClinicalTrials.gov: NCT02216370.
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Background
Stroke has consistently been the 2nd leading cause of
death in the age group of 60 plus worldwide [1]. Re-
cently, it has become the 4th leading cause of death and
the 1st leading cause of serious long-term disability in
the USA [2]. Accurate definition of stroke etiology is
crucial for the most effective management of the disease.
Cryptogenic stroke (CS), according to the TOAST
classification, is defined as an ischemic stroke with
undeterminable etiology, despite extensive evaluation
[3]. Stroke might be cryptogenic for several reasons: 1)
evaluation is not carried out at the time of event; 2) in-
vestigation is not sufficiently extensive; or 3) there are
other unknown causes. Therefore the proportion of CS
depends on the speed and wider-than-routine range of
diagnostic evaluation. Epidemiological observational trials
using standardized stroke etiological classification report
20–40 %, in some cases up to 50 % incidence of unre-
vealed causes [4–6].
Cardio-embolic stroke is the most frequently predicted
cause of CS in studies (58 %) [7, 8]. The most frequent
cause of cerebral cardio-embolism, as well as the most
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common cardiac arrhythmia, is atrial fibrilation (AF).
The incidence of stroke in people with non-valvular AF
is estimated to be 5 times higher than in people without
AF [9]. It has been suggested that paroxysmal AF (PAF)
is more prevalent than chronic AF in stroke and TIA pa-
tients, and they both appear to carry very similar stroke
risk [10].
Episodes of PAF may reoccur with variable frequency
and their detection has been made possible by ECG
monitoring. Short and usually asymptomatic presenta-
tions of PAF (also occult PAF) may remain undetected
by routine arrhythmia screening methods. Incidence of
newly identified PAF varies widely depending on the
type of cardiac monitoring devices, the delay in monitor-
ing after stroke onset and the monitoring duration. De-
tection rate of PAF with external ECG monitoring in
patients after CS has been recorded between 5 and 20 %
[11–13]. An insertable cardiac monitor (ICM) automat-
ically provides non-stop long-term ECG recording with
very high sensitivity and specificity for PAF detection.
Studies using ICM have suggested a detection rate of ap-
proximately 25 % [14–16].
In our study we are focusing on a possible correlation
between detection of atrial fibrillation by implantable ECG
loop, and PITX2 and/or ZFHX3 gene mutations in crypto-
genic stroke/TIA patients. A correlation could lead to im-
plementation of this genomic approach to cryptogenic
stroke/TIA diagnostics and management [17, 18].
Methods
Objective and endpoints
The objective of our study is to determine the propor-
tion of patients with CS or cryptogenic TIA (CTIA) that
have underlying PAF in comparison with control group.
PAF is defined as an episode of irregular heart rhythm
without detectable P waves lasting more than 30 s. Pri-
mary endpoints are the first documented PAF episode
after CS or CTIA and incidence of PITX2 and ZFHX3
genes mutation. Secondary endpoints include recurrent
stroke or TIA, new ischemic lesions found by brain im-
aging (CT and/or MRI), the size of left atrium (TTE/
TEE), and relevant treatment changes (e.g. oral anti-
coagulant drugs). The follow-up of patient and control
groups will last 12 months.
Study participants
The study will analyse data from at least 100 patients with
CS or CTIA admitted to the Department of Neurology in
Nitra between 2014 and 2018 as well as at least 30 age-
and sex-matched volunteers with no known vascular die-
sease in the control group. The study protocol has been
approved by the Ethics Committee of the Faculty Hospital
in Nitra (Slovak Republic). A written informed consent
will be obtained from all study participants or their legal
representatives.
Inclusion criteria
1. CS or CTIA within 72 h from symptom onset
2. Age ≥ 18 years
3. CS: modified Rankin Scale (mRS) ≤ 4 at discharge (to
ensure patient compliance)
4. CTIA: ABCD2 score ≥ 4
5. Ability and willingness of the patients or their legal
representatives to understand the study instructions,
both verbal and written, in accordance with ICH,
GCP and legislation of the Slovak Republic
Exclusion criteria
1. Known etiology of stroke/TIA
2. Untreated hyperthyroidism
3. Myocardial infarction within 1 month of stroke/
TIA onset
4. Coronary bypass within 1 month of stroke/TIA
onset
5. Valvular disease requiring urgent surgery
6. Documented AF or flutter
7. Patent foramen ovale
8. Permanent indication for oral anticoagulation
therapy
9. Long-term steroid therapy > 30 days
10.Participation in another clinical trial aimed at
experimental pharmacologic therapy
11.Chronic inflammatory disease (rheumatoid arthritis,
inflammatory bowel diseases, lupus erythematosus
etc.)
12.Severe co-morbidity not compatible with 12 months
follow-up
13.Pregnant and breastfeeding women
14.Indication for implantation of pacemaker,
implantable cardioverter defibrillator or implantable
pulse generator
Imaging and laboratory testing
Stroke diagnosis is accepted only when supported by
consistent findings on CT and/or MRI. To identify the
location and size of ischemic infarction, and to exclude
intracranial hemorrhage or other pathology, standard
non-contrast CT examination is performed initially after
stroke symptom onset. When convincing lesions are not
visible on CT, the patients undergo brain MRI (including
DWI) to confirm ischemic etiology. Following extensive
imaging and laboratory testing, we are using the TOAST
criteria to classify the stroke as cryptogenic. Only TIA
patients with symptoms of speech problems, limb
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weakness or hemianopia (ABCD2 score) are considered
and enrolled when CTIA is confirmed. To detect PAF,
patients undergo 48-h ECG Holter monitoring within
7 days after stroke/TIA onset and only those without
documented AF have implanted the ICM device (RE-
VEAL XT, REVEAL LINQ, Medtronic Inc., Minneapolis,
USA). Both patient and control groups are monitored
for 12 months. Patients’ follow-up visits are scheduled 1,
6, and 12 months after stroke/TIA onset and every
6 months thereafter until clinical study closure with
extra visits in case of any new stroke/TIA symptoms.
Disability of patients is classified according to the mRS
and Barthel Index score. The healthy control partici-
pants undergo assessment at visit scheduled 1, 6, and
12 months after the implantation. Except standard blood
laboratory analysis, complete vasculitis and thrombo-
philia testing panels are performed. Analysis of PITX2
(chromosome 4q25) and ZFHX3 (chromosome 16q22)
gene polymorphisms are evaluated by PCR with genetic
variation analysis such as restriction analysis (RFLP),
high resolution melting (HRM), or allele-specific PCR.
To analyse the data, descriptive statistics, statistical
tests for differences, and correlation analyses will be
used. This prospective and observational study is regis-
tered at www.clinicaltrials.gov with study identifier
NCT02216370.
Discussion
Unrecognized PAF and the consequent lack of prophylac-
tic anticoagulant treatment may result in significant mor-
bidity first presenting as a heart failure, stroke, systemic
embolism, and occasionally death. It is generally accepted
that intermittent ECG monitoring (Holter ECG) has low
sensitivity to identify patients with PAF. The commonly
used 24-h Holter ECG monitoring has been found to
reach PAF diagnostic sensitivity of 2.4–9.4 % [19–21].
Longer continuous non-stop ECG monitoring has been
shown to increase PAF detection. In a sub-study of
TRENDS, a single 24-h Holter ECG diagnosed PAF in
3 %, whereas 7, 21, or 30 days of monitoring diagnosed
PAF in 6, 9, or 11 %, respectively [22]. The EMBRACE
study (The 30-Day Cardiac Event Monitor Belt for Re-
cording Atrial Fibrillation After a Cerebral Ischemic
Event) used noninvasive ambulatory ECG monitoring in
patients with cryptogenic stroke or TIA for 30 days. De-
tection of atrial fibrillation improved fivefold and indica-
tion of anticoagulant treatment nearly doubled when
compared with standard practice of short-duration ECG
monitoring. AF was detected in 16.1 % of patients in the
intervention group, compared with 3.2 % in the control
group [23]. ICM devices for long-term ECG monitoring
have been used primarily for differential diagnosis of syn-
cope [24]. Cotter et al. reported “Reveal XT” PAF identifi-
cation in 25.5 % (13 patients) of 51 patients with
unexplained stroke [14]. Sensitivity and specificity of “Re-
veal XT” device for PAF was detected to be 96.1 and
85.4 % respectively (3-year non-stop monitoring) [25]. A
large randomized clinical trial The Cryptogenic Stroke
and Underlying Atrial Fibrillation trial (CRYSTAL AF)
compared long-term ECG monitoring by ICM with con-
ventional ECG Holter monitoring in patients with recent
CS. After 12 months ICM monitoring detected over 7
times more patients with PAF than ECG Holter monitor-
ing. Three-year follow-up detected 30 % PAF occurrence
in the ICM group compared to 3 % in the Holter group
[26]. Choe evaluated sensitivity and negative predictive
value (NPV) of various external monitoring techniques in
a cryptogenic stroke cohort. Simulated intermittent moni-
toring strategies were compared with continuous rhythm
monitoring in 168 ICM patients of the CRYSTAL AF trial.
Short-term monitoring included a single 24-h, 48-h and
7-day Holter, and 21-day and 30-day event recorders. Peri-
odic monitoring consisted of monthly monitoring by 24-h
Holters and quarterly monitoring by 24-h, 48-h and 7-day
Holters. For a single monitoring period, sensitivity for AF
diagnosis was lowest with 24-h Holters (1.3 %) and highest
with 30-day event recorders (22.8 %). NPV ranged from
82.3 to 85.6 % for all single external monitoring strategies.
Quarterly monitoring with 24-h Holters had 3.1 % sensi-
tivity, whereas quarterly 7-day monitors increased it to
20.8 %. NPV of various types of repetitive periodic moni-
toring were similar at 82.6 to 85.3 %. Long-term continu-
ous monitoring was superior in detecting AF compared to
all types of intermittent monitoring evaluated (p <0.001)
[27]. Ritter et al. presented 17.0 % PAF detection in ICM
group in comparison with 1.7 % in 7-day ECG Holter
group (p = 0.0077) [28].
Finding a new algorithm for detecting PAF in stand-
ard clinical practice should be of great interest as it
would allow early indication of anticoagulant therapy in
stroke/TIA patients. Additional information that would
help to characterize stroke subtype could be provided
by genetic data. Study of gene polymorphisms associ-
ated with an increased risk of AF suggests that subtle
alterations in developmental factors, cell signalling,
extracellular matrix regulation, and ion channels func-
tion are involved in arrhythmia pathogenesis. Large
genome-wide association studies (GWAS) have found
that the genetic markers close to the PITX2 gene on
chromosome 4q25 and to the ZFHX3 gene on 16q22
are associated with both AF and cardio-embolic stroke
[17, 18]. The PITX2 gene plays a critical role in devel-
opment of left atrium and pulmonary vein myocardium.
This particular region has been implicated to initiate
and maintain AF. The expression patterns of the
ZFHX3 gene in human cardiac and pulmonary tissue
are not clear, nor are the mechanisms by which variants
in this gene may predispose to AF.
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Conclusion
Cardioembolic TIA and stroke cause high rate disability
and mortality worldwide. As cardio-embolic etiology is
responsible for up to 58 % of CS, appropriate high-
resolution cardiac monitoring plays a crucial role in ar-
rhythmias detection after CTIA/CS. Early PAF diagnosis
allows to start immediate anticoagulation therapy in
order to reduce TIA/stroke recurrence. The expression
profile of the selected genes may be very useful in select-
ing high-risk PAF individuals who could then undergo
extensive ECG monitoring with no history of cerebro-
vascular disease.
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